The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of continuing osimertinib with chemotherapy in the post-progression setting on progression-free survival among patients with metastatic epidermal growth factor receptor (EGFR) positive non-small cell lung cancer.
 
Tejas Patil
Stock and Other Ownership Interests - crispr therapeutics; Guardant Health; Novartis; Pfizer; Roche/Genentech
Honoraria - Aptitude Health; AstraZeneca; Physicans' Education Resource; Roche/Genentech
Consulting or Advisory Role - Guidepoint Global
 
David Chun Cheong Tsui
No Relationships to Disclose
 
Andrew Nicklawsky
No Relationships to Disclose
 
Erin Lynn Schenk
Honoraria - Roche/Genentech; Takeda
Consulting or Advisory Role - Abbvie; Guidepoint Global
Speakers' Bureau - Physicans' Education Resource
Other Relationship - Elsevier
 
William T. Purcell
No Relationships to Disclose
 
Paul A. Bunn
Consulting or Advisory Role - Ascentage Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; CStone Pharmaceuticals; Genentech/Roche; Imedex; Imedex; Merck; viecure
Research Funding - Genentech (Inst)
 
Jose Maria Pacheco
Honoraria - Genentech/Roche (Inst)
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Blueprint Medicines (Inst); Gerson Lehrman Group; Hengrui Pharmaceutical ; Jazz Pharmaceuticals; Pfizer; Takeda (Inst)
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; Daiichi Sankyo/UCB Japan; Pfizer; Takeda
 
D. Ross Camidge
Honoraria - Abbvie; Amgen Astellas BioPharma; Anchiano; Apollomics; AstraZeneca; bio-thera; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Elevation Oncology; EMD Serono; GlaxoSmithKline; Helsinn Therapeutics; Inivata (Inst); Janssen; Kestrel Labs; Lilly; Mersana; Nuvalent, Inc.; OnKure; Pfizer; QiLu Pharmaceutical; Ribon Therapeutics; Roche; Sanofi; Seagen; takeda; Turning Point Therapeutics
Research Funding - Takeda